Core Insights - Cycurion, Inc. is a leader in IT cybersecurity solutions and AI, focusing on protecting healthcare organizations from emerging cyber threats [1][4] - The company will participate in the NACCHO360 conference, where executives will discuss current cybersecurity trends and defensive strategies for healthcare [2][3] Company Overview - Cycurion is based in McLean, Virginia, and specializes in cybersecurity, program management, and business continuity [4] - The company utilizes its AI-enhanced ARx platform to provide innovative services to clients, including government and healthcare sectors [4] Industry Context - The healthcare sector is increasingly targeted by cyber threats such as ransomware, AI-driven botnets, and phishing campaigns [3] - There is a growing cybersecurity arms race between AI-driven good and bad actors, necessitating advanced defensive strategies [3][7] Event Details - Michael A. Phillips and W. Eric Singleton will lead a panel titled "Hacking Health: Emerging Cyber Threats and Defensive Strategies for Healthcare and Public Health Organizations" at NACCHO360 [2][3] - The session will cover the latest cyber threats and how to mitigate risks using technologies like deception tools and Zero Trust frameworks [3][7] Partnership Announcement - Cycurion has been announced as NACCHO's newest Diamond Affiliate Business Partner, introducing the co-branded cybersecurity solution, NACCHO Cyber Shield [3]

Cycurion unveils Cyber Shield Sales Presence at the NACCHO360 conference in Anaheim, CaliforniaMCLEAN, Va., July 10, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces a strategic, diamond level partnership with the National Association of County and City Health Officials (NACCHO), the voice of the over 3,300 local health departments across the country. The partnership will provide its Managed Security Services ...

Core Insights - PharmaTher Holdings Ltd. aims to become a global leader in ketamine-based pharmaceuticals, with a clear strategy for regulatory approval and international expansion [1][3] Regulatory Milestones - The FDA has set an approval goal date of August 9, 2025, which is a significant milestone for the company, potentially unlocking a multi-billion-dollar market opportunity [3][7] - The current global market for ketamine is valued at $750 million and is projected to grow at a CAGR of 16.4%, reaching approximately $3.42 billion by 2034 [3] Financial Position - The company is fully funded for all planned operations leading up to the FDA approval goal date and the initial U.S. commercial launch of its ketamine product [5][7] - PharmaTher has no plans for new equity or debt financing before the FDA approval date, indicating confidence in its current financial position [6][7] Commercial Strategy - The manufacturing of the ketamine product is based in the U.S., ensuring supply chain security and quality control [7][8] - PharmaTher is preparing for international regulatory submissions in Europe, the UK, Canada, Japan, and the APAC regions, expected to begin in the second half of 2025 [7][8] Expansion and Innovation - The company is exploring new therapeutic applications for ketamine, inspired by bipartisan support for psychedelic-assisted therapies [9] - PharmaTher aims to broaden its clinical pipeline, focusing on indications such as Parkinson's disease, ALS, and CRPS, as well as novel delivery systems [7][9] Leadership Vision - The CEO emphasizes the upcoming FDA approval goal date as a critical starting point for global expansion and new therapeutic indications [10]

Contract awards build upon Cycurion’s other recent sales wins that have led to record backlog and positioned the company for a strong second half to 2025MCLEAN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces the award of several new contracts totaling over $8 million. These agreements, secured with government and commercial clients, reinforce Cycurion’s position as a trusted partner in prote ...

Core Viewpoint - PharmaTher Holdings Ltd. has received a U.S. patent for the use of ketamine in treating Amyotrophic Lateral Sclerosis (ALS), significantly enhancing its intellectual property portfolio and clinical development program [1][2][3] Company Overview - PharmaTher is focused on unlocking the pharmaceutical potential of ketamine, particularly for severe neurological disorders [1][3][8] - The company aims to address unmet medical needs in various fields, including surgery, pain, mental health, and neurological conditions [8] Patent and Regulatory Designations - The newly granted U.S. Patent No. 12,128,012, expiring on May 14, 2041, provides long-term protection for the specific method of using ketamine to treat ALS [7] - The company holds an Orphan Drug Designation (ODD) from the FDA, which offers seven years of market exclusivity post-approval, tax credits for clinical trials, exemption from FDA application fees, and regulatory guidance [7] Market Opportunity - The ALS treatment market is projected to exceed USD $1.04 billion by 2030, driven by high unmet needs and a dedicated patient advocacy community [7] - Approximately 5,000 new ALS cases are diagnosed annually in the U.S., with an estimated 30,000 individuals currently living with the disease [7] Strategic Positioning - The combination of the new patent and FDA ODD creates a strong strategic advantage for PharmaTher, allowing the company to advance its clinical program and pursue strategic partnerships [6][7] - The company is positioned to deliver potentially life-altering therapies to patients with urgent medical needs [6][3]

当钢铁轰鸣的城市记忆逐渐褪去，代码之光正点亮武汉的数字化未来。 6月13日，以"慧聚江城数智领航"为主题的第三届软件创新发展大会在武汉举行。大会汇聚1200名行业 精英，超过45亿元项目签约落槌，一场构筑软件产业新生态的雄心，在武汉澎湃激荡。 "武汉软件产业的发展自20世纪90年代萌芽，发展至今已从'打工仔''包工头'占主导，蜕变至'创新者''领 军者'唱主角。这不仅是产业形态的升级，更是城市扩大税源、实现高质量发展的核心增长点。"武汉市 软件协会相关负责人介绍。 达梦数据库成功登陆科创板，开源鸿蒙武汉创新中心落地生根......这些标志性事件背后，是武汉锚定"国 产替代+技术跃迁"双轨战略的清晰路径。这座城市不再甘于产业链跟随，而是以"自主创新+开源创 新"为双引擎，聚焦基础软件、工业软件等"卡脖子"领域，并以网络安全、地球信息空间及汽车软件三 大特色产业领域为突破口，力图争夺软件创新的制高点。 "当武汉软件产业产值翻一番，武汉GDP将有极大希望突破三万亿大关，重塑区域竞争格局。"一位业内 专家判断，软件产业正成为武汉撕掉重工业标签的重要抓手，其软硬实力的融合，将驱动武汉成为引领 中部地区崛起的强力"火车头 ...

文 | 美好生活博览会报道组 李思阳 在这个初夏的北京，一场融合科技、文化、生活的盛宴正在悄然酝酿。 想象这样一个场景：当你刚用完眼底照片预判健康情况，转身看到机器狗摇着尾巴递来展会 地图，隔壁展区的基因检测仪正告诉你今晚喝酒的"安全额度"，转角处汪小菲的直播间飘 来麻六记酸辣粉的香气，混着二次元音乐飘向你的心间。 ——这不是科幻电影的片场，而是将在 2025 首届美好生活博览会（简称"好博会"）实现 的真实图景。 6 月 27 日至 29 日，当阿里巴巴、京东、拼多多、抖音电商四大巨头首次联合，当脑机接 口、人形机器人等黑科技集体走出实验室，当二次元 COSER 带来动漫世界，这场以"美好 生活新场景，内外循环新动能"为主题的盛会，正用无数令人尖叫的亮点，为你我撕开未来 生活的一道裂缝。 电商"联盟"首秀： 四大平台织就消费新生态 # 阿里京东拼多多抖音首次联合 # 的热搜词条还在发烫，展会的四大平台展区也将掀起消 费风暴。 值得注意的是，这是阿里巴巴、京东、拼多多、抖音电商的首次联合，好博会创新性地实现 整合头部电商平台资源。这场电商巨头的"世纪同框"绝非简单的摊位拼接，巨头们凝聚的 势能，将为中国制造注 ...

Core Insights - PharmaTher Holdings Ltd. is focused on developing ketamine-based therapies and supports the FDA's new Commissioner's National Priority Voucher (CNPV) program to expedite the regulatory review process for its products [1][2][7] - The CNPV program significantly reduces the review time for drug applications from approximately 10-12 months to 1-2 months, allowing for accelerated approval if legal requirements are met [2] - PharmaTher has a robust chemistry, manufacturing, and controls (CMC) package for its ketamine product, with an FDA approval goal date set for August 9, 2025 [3] Clinical Developments - The company has promising clinical data for its ketamine therapies targeting rare and near-rare disorders, including Parkinson's disease and Complex Regional Pain Syndrome [4] - PharmaTher is developing innovative delivery systems such as KETAPATCH™, a microneedle patch, and a wearable pump, which aim to provide easier administration compared to traditional intravenous infusions [4] Regulatory Designations - The FDA has granted five orphan drug designations to PharmaTher for ketamine treatments addressing conditions like Amyotrophic Lateral Sclerosis (ALS) and Rett Syndrome [5] - These designations highlight the company's commitment to addressing critical unmet medical needs, particularly in mental health and pain management [6] Strategic Positioning - PharmaTher aims to leverage the CNPV program to enhance its development timeline and deliver value to patients and shareholders, aligning with national health priorities [7] - The company is positioned to become a leader in the pharmaceutical development of ketamine through its focus on novel, intellectual property-protected delivery systems [7]

Cycurion may now provide cybersecurity services and products to the 30 ICUF member institutionsMCLEAN, Va., June 12, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces they have partnered with ICUF as a Preferred Vendor to bring a line of robust cybersecurity solutions to 30 ICUF member institutions. Recognizing that higher education institutions manage vast amounts of sensitive data—including personal, finan ...

Core Viewpoint - Goldman Sachs provided key insights on AstraZeneca at its 46th Global Healthcare Conference, highlighting the company's management's reaffirmation of limited impact from potential drug tariffs and a clearer path to achieving $80 billion in revenue by 2030, alongside a target operating profit margin of around 35% [1] Group 1: Financial Outlook - AstraZeneca aims for an operating profit margin of approximately 35% while acknowledging uncertainties such as the inclusion of Farxiga in China's volume-based procurement in late 2025 and potential price reductions in the U.S. due to the Inflation Reduction Act (IRA) [2] - The company expects revenue growth and cost control to jointly drive profit margin improvements, with a projected impact of a few percentage points on total revenue from the redesign of the Medicare Part D program in 2025 [2] - Goldman Sachs maintains a "Buy" rating on AstraZeneca with a 12-month price target of $97, indicating nearly a 33% upside from the stock's closing price on June 9 [1] Group 2: Drug Development and Pipeline - AstraZeneca is optimistic about the Phase 3 trial of baxdrostat, learning from previous Phase 2 trials, and expects peak sales of $5 billion, with half from monotherapy and half from combination therapy with dapagliflozin [3] - The company emphasizes the importance of initiating cardiovascular, renal, and metabolic disease (CVRM) drug trials early to gather sufficient data for reimbursement purposes, despite these trials not being required for regulatory approval [3] - AstraZeneca is confident in the prospects of Enhertu for first-line treatment in HER2-positive breast cancer, reporting about a 50% complete response rate in metastatic patients [4] Group 3: Regulatory and Market Considerations - AstraZeneca's management noted uncertainties regarding the implementation of Most Favored Nation clauses and the IRA's role in lowering drug prices, while supporting increased healthcare budgets in European countries to foster innovation [2] - The company is increasing its investment in biologics while continuing to invest in small molecule drugs, such as oral GLP-1 and PCSK9 inhibitors [2] - AstraZeneca does not foresee ESR1 mutation testing as a barrier to the promotion of camizestrant, citing several operational advantages and prior experience with BRCA testing [3]